Early detection and aggressive treatment of prostate cancer: Groping in the dark

Journal of General Internal Medicine

Volumn 15, Issue 10, 2000, Pages 749-751

  Barry, M J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

BIOPSY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0033764193     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2000.00816.x     Document Type: Review

References (20)

1. Prostate cancer screening and beliefs about treatment efficacy: A national survey of primary care physicians and urologists
2. The U.S. Postal Service and cancer screening-stamps of approval?
3. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates
4. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria
5. Prostate carcinoma incidence and patient mortality. The effects of screening and early detection
6. Cancer surveillance series: Interpreting trends in prostate cancer-Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
7. Screening for cervical cancer
8. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer
9. Lowering PSA cutoffs to enhance detection of curable prostate cancer
10. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older
11. Extended field prostate biopsy enhances cancer detection
12. Extended field prostate biopsies: Too much of a good thing?
13. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
14. Prostate cancer detection at low prostate specific antigen
15. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
16. The incidence of prostate cancer in the PSA reflex range of 2.5 and 4.0 ng/mL
17. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
18. Population-based study of long-term survival in patients with clinically localised prostate cancer
19. Patient-reported complications and follow-up treatment after radical prostatectomy. The national medicare experience; 1988-1990
20. A decision analysis for treatment of clinically localized prostate cancer